Clinical trial · Observational
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
Prospective Clinical Study of 18F-mFBG PET Imaging in Neuroblastoma
NCT06852807CI-TRIAL-00093382recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-MFBG | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 18F-MFBG PET/CT in Neuroblastoma
- description
- Each patient receive a single intravenous injection of 18F-MFBG 2-5 MBq/kg and undergo PET/CT or PET/MR scan after 60 min post-injection.
- interventionNames
- Drug: 18F-MFBG
Primary outcomes (1)
- measure
- Diagnostic efficacy
- timeFrame
- through study completion, an average of 1.5 year
- description
- Sensitivity, specificity, positive and negative predictive value of 18F-mFBG PET/CT and PET/MR Imaging in neuroblastoma
Secondary outcomes (2)
- measure
- 18F-mFBG PET performence compared with other images
- timeFrame
- up to 24 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 0-18 years old, with legal guardian; 2. Clinically suspected or confirmed patients with neuroblastoma; 3. If the patient is under 8 years old or unable to write, his/her guardian should understand and comply with the requirements of the study. If the patient is 8 years old or older and has written ability, both the patient and his/her guardian must sign the informed consent. Exclusion Criteria: 1. Patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system diseases; 2. Patients who have received ionizing radiation outside the scope of this experiment for other clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv. 3. Patients who have received experimental drugs or devices (with uncertain efficacy or safety) within one month; 4. Patients with any condition that the principal investigator of this study deems may cause harm or potential harm in any aspect related to this trial.
References
Publications (0)
Data not yet available
No reference posted for this study.